We Think That There Are More Issues For Jiangsu Canopus Wisdom Medical TechnologyLtd (SZSE:301290) Than Just Sluggish Earnings
We Think That There Are More Issues For Jiangsu Canopus Wisdom Medical TechnologyLtd (SZSE:301290) Than Just Sluggish Earnings
Jiangsu Canopus Wisdom Medical Technology Co.,Ltd.'s (SZSE:301290) recent weak earnings report didn't cause a big stock movement. We think that investors are worried about some weaknesses underlying the earnings.
江蘇飛凡智慧醫療科技有限公司(SZSE:301290)最近的疲弱收益報告沒有引起股票大動。我們認爲投資者擔心收益背後的一些弱點。
The Impact Of Unusual Items On Profit
除了稀釋之外,還應該注意的是,萬集科技在過去12個月中因不尋常項目獲得了價值人民幣3.5萬元的利潤。雖然我們希望看到利潤增加,但當這些不尋常項目對利潤做出重大貢獻時,我們會更加謹慎。我們對全球大部分上市公司的數據進行了分析,發現不尋常項目往往是一次性的。這正如我們所期望的那樣,因爲這些提升被描述爲"不尋常"。相對於其利潤而言,萬集科技在2021年12月前的不尋常項目貢獻大。因此,我們可以推斷出,這些不尋常項目正在使其財務利潤顯著增強。
Importantly, our data indicates that Jiangsu Canopus Wisdom Medical TechnologyLtd's profit received a boost of CN¥5.8m in unusual items, over the last year. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we analysed the vast majority of listed companies worldwide, we found that significant unusual items are often not repeated. And that's as you'd expect, given these boosts are described as 'unusual'. If Jiangsu Canopus Wisdom Medical TechnologyLtd doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.
重要的是,我們的數據顯示,江蘇飛凡智慧醫療科技有限公司的利潤在過去一年中因爲飛凡項目增加了580萬人民幣。雖然我們喜歡看到利潤增加,但當飛凡項目對利潤有重大貢獻時,我們會更加謹慎。當我們分析全球絕大多數上市公司時,我們發現重大的飛凡項目通常不會重複出現。這是可以預期的,因爲這些提升被描述爲「飛凡」。如果江蘇飛凡智慧醫療科技有限公司不再看到這種貢獻的重複,那麼在其他條件不變的情況下,我們預計其利潤將在當前年份下降。
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Jiangsu Canopus Wisdom Medical TechnologyLtd.
注意:我們始終建議投資者檢查資產負債表健康狀況。點擊此處以查看我們對江蘇飛凡智慧醫療科技有限公司資產負債表的分析。
Our Take On Jiangsu Canopus Wisdom Medical TechnologyLtd's Profit Performance
我們對江蘇飛凡智慧醫療科技有限公司的利潤表現的看法
We'd posit that Jiangsu Canopus Wisdom Medical TechnologyLtd's statutory earnings aren't a clean read on ongoing productivity, due to the large unusual item. Because of this, we think that it may be that Jiangsu Canopus Wisdom Medical TechnologyLtd's statutory profits are better than its underlying earnings power. Sadly, its EPS was down over the last twelve months. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. So while earnings quality is important, it's equally important to consider the risks facing Jiangsu Canopus Wisdom Medical TechnologyLtd at this point in time. For example - Jiangsu Canopus Wisdom Medical TechnologyLtd has 1 warning sign we think you should be aware of.
我們認爲,江蘇飛凡創智醫療科技有限公司的法定收益並不能準確反映其持續盈利能力,因爲存在大額飛凡項。因此,我們認爲江蘇飛凡創智醫療科技有限公司的法定利潤可能比其潛在盈利能力更好。不幸的是,其每股收益在過去12個月內下降了。當然,在分析其收益時,我們只是觸及到了表面,還可以考慮利潤率、預測增長和投資回報率等其他因素。因此,儘管收益質量很重要,但同樣重要的是要考慮江蘇飛凡創智醫療科技有限公司目前面臨的風險。例如,我們認爲江蘇飛凡創智醫療科技有限公司存在1個警示信號,您應該注意。
This note has only looked at a single factor that sheds light on the nature of Jiangsu Canopus Wisdom Medical TechnologyLtd's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.
本文只關注了一個可以揭示江蘇飛凡創智醫療科技有限公司利潤性質的因素。但如果您能夠將注意力集中在細枝末節上,還有更多可以發現的內容。例如,許多人認爲高淨資產回報率是良好經營經濟狀況的指標,而其他人則喜歡「追蹤資金」,尋找內部人士正在買入的股票。因此,您可能希望查看這個免費的高淨資產回報率公司收藏集,或者這個高內部持股的股票清單。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。